NASDAQ:PAVM PAVmed - PAVM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.37 -0.01 (-2.61%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.36▼$0.4550-Day Range$0.36▼$0.5752-Week Range$0.35▼$2.34Volume1.25 million shsAverage Volume478,401 shsMarket Capitalization$36.76 millionP/E RatioN/ADividend YieldN/APrice Target$3.56 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability PAVmed MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside853.8% Upside$3.56 Price TargetShort InterestBearish8.52% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector851st out of 1,004 stocksSurgical & Medical Instruments Industry85th out of 104 stocks 3.3 Analyst's Opinion Consensus RatingPAVmed has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.56, PAVmed has a forecasted upside of 853.8% from its current price of $0.37.Amount of Analyst CoveragePAVmed has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.52% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in PAVmed has recently decreased by 3.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePAVmed has received a 63.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Medical devices engineering", "Intravenous therapy equipment", and "Biopsy systems" products. See details.Environmental SustainabilityThe Environmental Impact score for PAVmed is -0.78. Previous Next 1.1 News and Social Media Coverage News SentimentPAVmed has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders13.20% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.98% of the stock of PAVmed is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPAVmed has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PAVmed (NASDAQ:PAVM) StockPAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.Read More Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Email Address PAVM Stock News HeadlinesMarch 17, 2023 | finance.yahoo.comPAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should KnowMarch 3, 2023 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023April 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...March 3, 2023 | finance.yahoo.comPAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023February 15, 2023 | finance.yahoo.comHere's Why PAVmed Inc. (PAVM) Looks Ripe for Bottom FishingJanuary 17, 2023 | finance.yahoo.comPAVmed and Lucid Diagnostics Provide Strategic Business UpdateJanuary 11, 2023 | finance.yahoo.comPAVmed and Lucid Diagnostics to Provide Strategic Business UpdateDecember 22, 2022 | finance.yahoo.comPAVmed Partners with Novosound on Ultrasound Imaging TechnologyApril 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...December 1, 2022 | finance.yahoo.comLucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer ResearchNovember 18, 2022 | seekingalpha.comPAVmed Inc. (PAVM) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comPAVmed Provides Business Update and Third Quarter 2022 Financial ResultsNovember 11, 2022 | finance.yahoo.comPAVmed to Participate in BTIG Digital Health ForumNovember 10, 2022 | finance.yahoo.comLucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services ForumNovember 9, 2022 | finance.yahoo.comLucid Diagnostics Commences Production of EsoCheck Devices with High-Volume ManufacturerNovember 3, 2022 | finance.yahoo.comPAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022November 2, 2022 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022October 18, 2022 | marketwatch.comPavmed Inc. Common Stock PAVM Pivots Trading Plans and Risk ControlsSeptember 18, 2022 | reuters.comPAVM.O - PAVmed Inc | Stock Price & Latest News | ReutersSeptember 10, 2022 | reuters.comPAVM.OQ - PAVmed Inc | Stock Price & Latest News | ReutersAugust 30, 2022 | businesswire.comPAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference - Business WireAugust 17, 2022 | benzinga.comNasdaq Down 75 Points After Fed Minutes; Crude Oil Rises 1.5% - BenzingaAugust 17, 2022 | finance.yahoo.comDoes PAVmed (NASDAQ:PAVM) Have A Healthy Balance Sheet?August 17, 2022 | businesswire.comPAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results - Business WireAugust 16, 2022 | seekingalpha.comPAVmed Non-GAAP EPS of -$0.17 beats by $0.03 (NASDAQ:PAVM) - Seeking AlphaAugust 16, 2022 | finance.yahoo.comPAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results - Yahoo FinanceAugust 16, 2022 | finance.yahoo.comPAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Email Address PAVM Company Calendar Last Earnings8/12/2021Today3/31/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PAVM CUSIPN/A CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.56 High Stock Price Forecast$8.25 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+738.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,980,000.00 Net MarginsN/A Pretax Margin-27,384.09% Return on Equity-172.76% Return on Assets-79.69% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual Sales$380,000.00 Price / Sales110.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book4.72Miscellaneous Outstanding Shares98,420,000Free Float85,429,000Market Cap$41.84 million OptionableNot Optionable Beta0.88 Key ExecutivesLishan AklogChairman & Chief Executive OfficerDennis M. McGrathPresident, Chief Financial Officer & SecretaryShaun M. O’NeilChief Operating Officer & Executive Vice PresidentBrian J. deGuzmanChief Medical OfficerJames MitchellVice President-Digital HealthKey CompetitorsSTRATA Skin SciencesNASDAQ:SSKNBrainsWayNASDAQ:BWAYCo-DiagnosticsNASDAQ:CODXGBSNYSE:GBSSeaStar MedicalNASDAQ:ICUView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 54,540 shares on 2/15/2023Ownership: 0.333%Morgan StanleySold 45,120 shares on 2/15/2023Ownership: 0.136%Verition Fund Management LLCSold 45,832 shares on 2/14/2023Ownership: 0.144%Wells Fargo & Company MNBought 57,533 shares on 2/13/2023Ownership: 0.375%Levin Capital Strategies L.P.Bought 130,000 shares on 2/13/2023Ownership: 0.286%View All Insider TransactionsView All Institutional Transactions PAVM Stock - Frequently Asked Questions Should I buy or sell PAVmed stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PAVM shares. View PAVM analyst ratings or view top-rated stocks. What is PAVmed's stock price forecast for 2023? 2 Wall Street research analysts have issued 12-month price targets for PAVmed's shares. Their PAVM share price forecasts range from $1.50 to $8.25. On average, they anticipate the company's stock price to reach $3.56 in the next year. This suggests a possible upside of 738.0% from the stock's current price. View analysts price targets for PAVM or view top-rated stocks among Wall Street analysts. How have PAVM shares performed in 2023? PAVmed's stock was trading at $0.48 at the start of the year. Since then, PAVM stock has decreased by 11.4% and is now trading at $0.4251. View the best growth stocks for 2023 here. When is PAVmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our PAVM earnings forecast. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) issued its quarterly earnings results on Thursday, August, 12th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Co-Diagnostics (CODX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), Onconova Therapeutics (ONTX) and Strongbridge Biopharma (SBBP). What is PAVmed's stock symbol? PAVmed trades on the NASDAQ under the ticker symbol "PAVM." Who are PAVmed's major shareholders? PAVmed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wells Fargo & Company MN (0.38%), Millennium Management LLC (0.33%), Levin Capital Strategies L.P. (0.29%), Verition Fund Management LLC (0.14%), Morgan Stanley (0.14%) and Belpointe Asset Management LLC (0.10%). Insiders that own company stock include Lishan Aklog, Matthew Sirovich, Michael J Glennon and Pavmed Inc. View institutional ownership trends. How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PAVmed's stock price today? One share of PAVM stock can currently be purchased for approximately $0.43. How much money does PAVmed make? PAVmed (NASDAQ:PAVM) has a market capitalization of $41.84 million and generates $380,000.00 in revenue each year. The company earns $-88,980,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. How can I contact PAVmed? PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The official website for the company is www.pavmed.com. The company can be reached via phone at (212) 949-4319 or via email at jmh@pavmed.com. This page (NASDAQ:PAVM) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.